Practice Management News

AriBio USA Inc. announced the enrollment of the first participants in a phase 3 trial to evaluate the efficacy of a novel therapeutic to treat those with early Alzheimer’s disease.

As the world continues to grapple with effects of the COVID-19 pandemic, individuals around the globe are still dealing with symptoms of SARS-CoV-2 infection for months, even years, after their initial infection.

Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press release.

Among children and adolescents in Israel, use of psychiatric emergency departments declined sharply during the first year of the COVID-19 pandemic, compared to the year prior, according to a study in BMC Psychiatry.

The Substance Abuse and Mental Health Services Administration announced the results of its annual national survey on drug use and health for 2021.

Patients who undergo procedures requiring anesthesia should be asked about cannabis use, according to new guidelines released today by the American Society of Regional Anesthesia and Pain Medicine.

For those with major depressive disorder, early intervention is crucial to address treatment-resistant depression, which may lead to higher disease burden on the patient and health care system, per a study published in JAMA Psychiatry.

Migraine has a bidirectional relationship with mental disorders such as anxiety and depression, and one may increase the risk of the other, researchers reported in Cureus.

The American Psychiatric Association said it is pleased that provisions in the Consolidated Appropriations Act of 2023 will promote access to mental health and substance use disorder care, according to a statement on its website.

Children with mental or behavioral health conditions are more likely to experience pharmacologic restraint in the ED if they are young, male or Black, according to a study published in Pediatrics.